Trial Profile
Intraoperative Detection of Cancer Tissue in Pancreatic Adenocarcinoma Using a VEGF-targeted Optical Fluorescent Imaging Tracer, A Multicentre Feasibility Dose Escalation Study
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Diagnostic use
- Acronyms PENGUIN
- 25 Jan 2020 Status changed from recruiting to discontinued.
- 25 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
- 25 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.